SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin receives USFDA’s nod for Zileuton Extended-Release Tablets

11 Nov 2019 Evaluate

Lupin has received approval for its Zileuton Extended-Release Tablets, 600 mg, from the United States Food and Drug Administration (USFDA), to market a generic equivalent of Zyflo CR Extended-Release Tablets, 600 mg, of Chiesi USA, Inc.

Lupin's Zileuton Extended-Release Tablets, 600 mg are indicated for prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older.

Zileuton Extended-Release Tablets, 600 mg had annual sales of approximately $43 million in the US. (IQVIA MAT September 2019).

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2495.55 3.10 (0.12%)
07-Jul-2026 09:09 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1905.00
Dr. Reddys Labs. 1355.80
Cipla 1482.70
Zydus Lifesciences 1143.85
Lupin 2495.55
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: